Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of Myriad Genetics, Inc (NASDAQ: MYGN) was $6.3 for the day, down -0.47% from the previous closing price of $6.33. In other words, the price has decreased by -$0.47 from its previous closing price. On the day, 1.05 million shares were traded. MYGN stock price reached its highest trading level at $6.365 during the session, while it also had its lowest trading level at $6.1.
Ratios:
Our analysis of MYGN’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.12 and its Current Ratio is at 2.33. In the meantime, Its Debt-to-Equity ratio is 0.57 whereas as Long-Term Debt/Eq ratio is at 0.55.
Wells Fargo Downgraded its Overweight to Equal Weight on May 07, 2025, while the target price for the stock was maintained at $6.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MYGN now has a Market Capitalization of 587246464 and an Enterprise Value of 654146432. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.71 while its Price-to-Book (P/B) ratio in mrq is 1.57. Its current Enterprise Value per Revenue stands at 0.793 whereas that against EBITDA is -24.967.
Stock Price History:
The Beta on a monthly basis for MYGN is 1.85, which has changed by -0.63604856 over the last 52 weeks, in comparison to a change of 0.12121439 over the same period for the S&P500. Over the past 52 weeks, MYGN has reached a high of $19.60, while it has fallen to a 52-week low of $3.76. The 50-Day Moving Average of the stock is -16.09%, while the 200-Day Moving Average is calculated to be -15.64%.
Shares Statistics:
MYGN traded an average of 1.38M shares per day over the past three months and 1261760 shares per day over the past ten days. A total of 93.10M shares are outstanding, with a floating share count of 88.59M. Insiders hold about 4.96% of the company’s shares, while institutions hold 98.03% stake in the company. Shares short for MYGN as of 1760486400 were 7761944 with a Short Ratio of 5.61, compared to 1757894400 on 8494919. Therefore, it implies a Short% of Shares Outstanding of 7761944 and a Short% of Float of 11.73.
Earnings Estimates
Myriad Genetics, Inc (MYGN) is presently subject to a detailed evaluation by 10.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is $0.0, with high estimates of $0.02 and low estimates of -$0.02.
Analysts are recommending an EPS of between $0.02 and -$0.02 for the fiscal current year, implying an average EPS of $0.01. EPS for the following year is $0.08, with 11.0 analysts recommending between $0.19 and -$0.03.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 12 analysts. It ranges from a high estimate of $211.8M to a low estimate of $205.8M. As of. The current estimate, Myriad Genetics, Inc’s year-ago sales were $210.6MFor the next quarter, 12 analysts are estimating revenue of $209.96M. There is a high estimate of $215.27M for the next quarter, whereas the lowest estimate is $206M.
A total of 13 analysts have provided revenue estimates for MYGN’s current fiscal year. The highest revenue estimate was $826.5M, while the lowest revenue estimate was $819.23M, resulting in an average revenue estimate of $822.3M. In the same quarter a year ago, actual revenue was $837.6MBased on 13 analysts’ estimates, the company’s revenue will be $867.59M in the next fiscal year. The high estimate is $879.4M and the low estimate is $846M.
